Abstract:Background: Food allergy prevalence has continued to rise over the past decade. While studies have reported threshold doses for multiple foods, large-scale multi-food allergen studies are lacking. Our goal was to identify threshold dose distributions and predictors of severe reactions during blinded oral food challenges (OFCs) in multi-food allergic patients. Methods: A retrospective chart review was performed on all Stanford-initiated clinical protocols involving standardized screening OFCs to any of 11 food allergens at 7 sites. Interval-censoring survival analysis was used to calculate eliciting dose (ED) curves for each food. Changes in severity and ED were also analyzed among participants who had repeated challenges to the same food. Results: Of 428 participants, 410 (96%) had at least one positive challenge (1445 standardized OFCs with 1054 total positive challenges). Participants undergoing peanut challenges had the highest ED50 (29.9 mg), while those challenged with egg or pistachio had the lowest (7.07 or 1.7 mg, respectively). The most common adverse event was skin related (54%), followed by gastrointestinal (GI) events (33%). A history of asthma was associated with a significantly higher risk of a severe reaction (hazard ratio [HR]: 2.37, 95% confidence interval [CI]: 1.36, 4.13). Higher values of allergen-specific IgE (sIgE) and sIgE to total IgE ratio (sIgEr) were also associated with higher risk of a severe reaction (1.49 [1.19, 1.85] and 1.84 [1.30, 2.59], respectively). Participants undergoing cashew, peanut, pecan, sesame, and walnut challenges had more severe reactions as ED increased. In participants who underwent repeat challenges, the ED did not change (p = 0.66), but reactions were more severe (p = 0.02). Conclusions: Participants with a history of asthma, high sIgEr, and/or high values of sIgE were found to be at higher risk for severe reactions during food challenges. These findings may help to optimize food challenge dosing schemes in multi-food allergic, atopic patients, specifically at lower doses where the majority of reactions occur. Trials Registration Number: ClinicalTrials. gov number NCT03539692; https://clinicaltrials.gov/ct2/show/NCT03539692.

Eliciting and stop dose during oral food challenges for peanut and common tree nuts in different age groups

Eliciting Dose and Safety Outcomes From a Large Dataset of Standardized Multiple Food Challenges

Eliciting dose is associated with tolerance development in peanut and cow’s milk allergic children

Low‐dose oral food challenges

Oral Food Challenge in Children with Tree Nut and Peanut Allergy: The Predictive Value of Diagnostic Tests

Predicting reactivity threshold in children with anaphylaxis to peanut

Successful introduction of peanut in sensitized infants with reported reactions at home

Safety and feasibility of peanut, tree nut, and sesame oral immunotherapy in infants and toddlers in a real-world setting

Can we predict severe reactions during peanut challenges in children?

Predicting the Outcome of Pediatric Oral Food Challenges for Determining Tolerance Development

Oral food challenges in children with a diagnosis of food allergy

Oral food challenge test results of patients with food allergy with specific IgE levels >100 UA/ml

Retrospective analysis of 120 cases with allergic reactions during oral food challenge test

Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy

Utility of food allergy thresholds

Oral immunotherapy for food allergy in children: is it worth it?

Diagnosing peanut allergy with skin prick and specific IgE testing

Prevalence and Characteristics of Accidental Ingestions Among Pediatric Food Allergy Patients

Timing of initial symptom onset during milk and wheat challenges: A retrospective study

Is Component-Specific Antibody Testing Sufficient to Replace the Oral Food Challenge in the Diagnostics of Peanut-Sensitized Children? A Proof-of-Concept Study

Epitope-Specific IgE at 1 Year of Age Can Predict Peanut Allergy Status at 5 Years